Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
11 results
  • Multiple Myeloma

19-893          Phase I

A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF CC-93269, A BCMA X CD3 T CELL ENGAGING ANTIBODY, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (View details on clinicaltrial.gov)

  • Lymphoma, Multiple Myeloma

21-245          Phase II

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma

19-054          Phase II

A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety And Tolerability, Pharmacokinetics And Preliminary Efficacy of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma, Cellular Therapy

18-604          Phase II

A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2). (View details on clinicaltrial.gov)

  • Cellular Therapy, Multiple Myeloma

20-518          Phase I

A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma

19-379          Phase II

A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma

20-074          Phase II

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma

19-719          Phase II

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen) (View details on clinicaltrial.gov)

Showing 1 - 10 of 11 results